Celyad Oncology SA (CYAD.BR)
EUR 0.48
(-0.83%)
EUR 0.48
(-0.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.76 Million EUR | 52.13% |
| 2022 | -39.69 Million EUR | 26.46% |
| 2021 | -25.41 Million EUR | -5.73% |
| 2020 | -15.73 Million EUR | 11.87% |
| 2019 | -27.45 Million EUR | 26.54% |
| 2018 | -36.56 Million EUR | -124.21% |
| 2017 | -55.69 Million EUR | 23.87% |
| 2016 | -21.98 Million EUR | 21.39% |
| 2015 | -28.07 Million EUR | -54.32% |
| 2014 | -15.31 Million EUR | -63.51% |
| 2013 | -12.06 Million EUR | -2607.55% |
| 2012 | -12 Million EUR | 106.92% |
| 2011 | -6.36 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.85 Million EUR | 0.0% |
| 2023 FY | - EUR | 47.89% |
| 2023 Q4 | -4.46 Million EUR | 0.0% |
| 2023 Q2 | -5.42 Million EUR | 0.0% |
| 2022 FY | - EUR | 26.46% |
| 2022 Q4 | -12.01 Million EUR | 0.0% |
| 2022 Q2 | -7.6 Million EUR | -1.97% |
| 2022 Q1 | -7.45 Million EUR | 9.91% |
| 2021 Q2 | -6.33 Million EUR | 1.25% |
| 2021 Q4 | -8.27 Million EUR | -36.26% |
| 2021 FY | - EUR | -5.73% |
| 2021 Q1 | -6.41 Million EUR | 0.94% |
| 2021 Q3 | -6.07 Million EUR | 4.14% |
| 2020 FY | - EUR | 11.87% |
| 2020 Q3 | -5.55 Million EUR | 63.58% |
| 2020 Q4 | -6.47 Million EUR | -16.68% |
| 2020 Q2 | -15.24 Million EUR | 0.0% |
| 2019 Q2 | -16.32 Million EUR | -146.39% |
| 2019 FY | - EUR | 26.54% |
| 2019 Q4 | -16.29 Million EUR | 0.0% |
| 2019 Q1 | -6.62 Million EUR | 59.02% |
| 2018 Q2 | -15.16 Million EUR | -67.33% |
| 2018 Q1 | -9.06 Million EUR | 32.15% |
| 2018 FY | - EUR | -124.21% |
| 2018 Q4 | -16.17 Million EUR | 0.0% |
| 2017 Q2 | -11.79 Million EUR | 0.19% |
| 2017 FY | - EUR | 23.87% |
| 2017 Q4 | -13.35 Million EUR | 0.0% |
| 2017 Q1 | -11.82 Million EUR | -98.61% |
| 2016 Q4 | -5.95 Million EUR | 0.0% |
| 2016 FY | - EUR | 21.39% |
| 2016 Q2 | -16.58 Million EUR | -201.78% |
| 2016 Q1 | -5.49 Million EUR | 59.9% |
| 2015 Q4 | -13.7 Million EUR | -95.95% |
| 2015 FY | - EUR | -54.32% |
| 2015 Q3 | -6.99 Million EUR | 52.43% |
| 2015 Q2 | -14.7 Million EUR | -110.21% |
| 2015 Q1 | -6.99 Million EUR | 29.78% |
| 2014 Q1 | -3.89 Million EUR | 40.95% |
| 2014 FY | - EUR | -63.51% |
| 2014 Q4 | -9.96 Million EUR | -156.08% |
| 2014 Q3 | -3.89 Million EUR | 35.18% |
| 2014 Q2 | -6 Million EUR | -54.28% |
| 2013 Q3 | -2.75 Million EUR | 50.39% |
| 2013 Q4 | -6.58 Million EUR | -138.79% |
| 2013 FY | - EUR | -2607.55% |
| 2013 Q1 | -2.75 Million EUR | 0.0% |
| 2013 Q2 | -5.56 Million EUR | -101.56% |
| 2012 Q2 | -314.68 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 106.92% |
| 2012 Q1 | -314.68 Thousand EUR | 0.0% |
| 2012 Q3 | -314.68 Thousand EUR | 0.0% |
| 2012 Q4 | -2.75 Million EUR | -776.66% |
| 2011 Q4 | -314.68 Thousand EUR | 80.37% |
| 2011 Q1 | -1.6 Million EUR | 0.0% |
| 2011 Q2 | -1.6 Million EUR | 0.0% |
| 2011 Q3 | -1.6 Million EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2010 Q4 | -1.6 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nicox S.A. | -16.23 Million EUR | 52.192% |
| European Medical Solutions | 59 Thousand EUR | 13257.627% |
| FERMENTALG | -10.51 Million EUR | 26.137% |
| argenx SE | -199.5 Million EUR | 96.109% |
| BioSenic S.A. | -6.79 Million EUR | -14.229% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 48.178% |
| Onward Medical N.V. | -35.23 Million EUR | 77.967% |
| Oxurion NV | -16.72 Million EUR | 53.596% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 66.145% |
| Financière de Tubize SA | 184.57 Thousand EUR | 4305.97% |
| UCB SA | 1.26 Billion EUR | 100.612% |